Buy Aurobindo Pharma: target of Rs 1024: Sharekhan

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Sharekhan's research report on Aurobindo Pharma

Aurobindo’s US business to stage a marked improvement led by sturdy pipeline of new products, expected traction in the lucrative injectables space and growth in the recently launched products. Further, Aurobindo is investing ~$180 -200 million (~Rs. 1,350-1,500 crore each) towards capacity expansion in FY2021 and FY2022 and encompassing areas of injectables and oral solids across geographies. Aurobindo’s sales and PAT are expected to clock a CAGR of 10% and 14%, respectively, over FY2020-FY2023.

Outlook

We retain our Buy recommendation on Aurobindo Pharma Limited (Aurobindo) with an unchanged PT of Rs. 1,024.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More